View Financial HealthUrteste 配当と自社株買い配当金 基準チェック /06Urteste配当金を支払った記録がありません。主要情報n/a配当利回り-6.2%バイバック利回り総株主利回り-6.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 12Urteste S.A. Enrolls First Patient in Panuri Test Clinical StudyUrteste S.A. has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the Fourth Quarter of this year. The study is proceeding according to schedule and within budget. Panuri is Urteste’s priority project and involves the development of a non-invasive diagnostic test for in vitro use, based on urine sample analysis. The primary objective of the study is to evaluate the effectiveness of the Panuri test in detecting pancreatic cancer, with the primary endpoints including the test’s sensitivity and specificity. The use of the Panuri test on the first study participant represents a significant step in the project’s implementation and confirms the transition to the active clinical study phase. The start of participant recruitment significantly reduces the risks characteristic of the preparatory and organizational phase of a clinical study, including those related to test production, the launch of study sites, and the initiation of the recruitment process. The study is multicenter and is being conducted in Poland, Hungary, and Italy. Ultimately, it will involve 30 centers in these countries. Urteste collaborates with experienced international partners. The study is being conducted as a CRO by the Finnish group Aurevia, while the German company Biotype is responsible for the production of the test as a CDMO. In the study, samples from 550 participants will undergo statistical analysis, including 400 in the target arm (patients with symptoms suggestive of pancreatic cancer) and 150 in the enriched arm (patients with a planned histopathological evaluation of the pancreas). The study results will form part of the documentation used in the certification process for the IVD (in vitro diagnostic) medical device developed by Urteste in Europe. Furthermore, they may potentially supplement the clinical data obtained in a planned study in the U.S. Development work on the Panuri test, completed in June 2025, provided preliminary data indicating the solution’s diagnostic potential, including a sensitivity of 89%, specificity of 75%, and diagnostic accuracy of 81% in the analyzed study population. The data obtained has attracted the interest of potential strategic partners. Urteste currently has 13 prototypes of diagnostic tests for cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas, and prostate, which together account for nearly 70% of all cancer-related deaths worldwide. The innovative technology developed by Urteste involves detecting cancers by measuring the activity of enzymes present in urine using specific tests that cause a change in urine color intensity, which may indicate the presence of cancer.お知らせ • Jun 02Urteste S.A., Annual General Meeting, Jun 26, 2026Urteste S.A., Annual General Meeting, Jun 26, 2026.New Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Dec 07Is Urteste (WSE:URT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Jul 19Urteste (WSE:URT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • May 29Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain TumoursUrteste S.A. developed a prototype IVD test for detecting brain tumours. Urteste now has a pipeline of 12 prototype diagnostic tests for the following cancers: pancreatic, brain, breast, stomach, bile ducts, ovary, endometrial, kidney, colorectal, lung, liver and prostate accounting collectively for nearly 70% of all cancer deaths worldwide. In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its project PANURI, a test for pancreatic cancer. Urteste’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error. PANURI - the pancreatic cancer test is Urteste's most advanced project. Pancreatic cancer is one of the worst prognosis cancers. A proof-of-concept study of 322 participants confirmed the high sensitivity (95.6%) and specificity (95.5%) of the PANURI test. Urteste is currently undergoing an FDA Q-Submission programme. In the MULTI-CANCER project, Urteste is developing a diverse portfolio of tests. The company already has prototypes of 12 diagnostic tests for the most common cancers. In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests. The company will then focus on preparing for clinical trials. Urteste holds polish patents and international patent applications for its technology. Urteste's patent strategy is to seek patent protection in countries that collectively generate around 90% of global GDP.お知らせ • May 21Urteste S.A., Annual General Meeting, Jun 14, 2024Urteste S.A., Annual General Meeting, Jun 14, 2024.お知らせ • Jan 19+ 3 more updatesUrteste S.A. to Report Q3, 2024 Results on Nov 28, 2024Urteste S.A. announced that they will report Q3, 2024 results on Nov 28, 2024New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (zł155.1m market cap, or US$38.0m).お知らせ • May 31Urteste S.A., Annual General Meeting, Jun 22, 2023Urteste S.A., Annual General Meeting, Jun 22, 2023, at 14:00 Central European Standard Time.お知らせ • May 28+ 1 more updateUrteste S.A. to Report First Half, 2023 Results on Sep 29, 2023Urteste S.A. announced that they will report first half, 2023 results on Sep 29, 2023お知らせ • Jan 26+ 3 more updatesUrteste S.A. to Report Q3, 2023 Results on Nov 13, 2023Urteste S.A. announced that they will report Q3, 2023 results on Nov 13, 2023決済の安定と成長配当データの取得安定した配当: URTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: URTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Urteste 配当利回り対市場URT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (URT)n/a市場下位25% (PL)2.8%市場トップ25% (PL)7.1%業界平均 (Biotechs)2.4%アナリスト予想 (URT) (最長3年)n/a注目すべき配当: URTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: URTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: URTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: URTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YPL 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 01:44終値2026/06/18 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Urteste S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.
お知らせ • Jun 12Urteste S.A. Enrolls First Patient in Panuri Test Clinical StudyUrteste S.A. has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the Fourth Quarter of this year. The study is proceeding according to schedule and within budget. Panuri is Urteste’s priority project and involves the development of a non-invasive diagnostic test for in vitro use, based on urine sample analysis. The primary objective of the study is to evaluate the effectiveness of the Panuri test in detecting pancreatic cancer, with the primary endpoints including the test’s sensitivity and specificity. The use of the Panuri test on the first study participant represents a significant step in the project’s implementation and confirms the transition to the active clinical study phase. The start of participant recruitment significantly reduces the risks characteristic of the preparatory and organizational phase of a clinical study, including those related to test production, the launch of study sites, and the initiation of the recruitment process. The study is multicenter and is being conducted in Poland, Hungary, and Italy. Ultimately, it will involve 30 centers in these countries. Urteste collaborates with experienced international partners. The study is being conducted as a CRO by the Finnish group Aurevia, while the German company Biotype is responsible for the production of the test as a CDMO. In the study, samples from 550 participants will undergo statistical analysis, including 400 in the target arm (patients with symptoms suggestive of pancreatic cancer) and 150 in the enriched arm (patients with a planned histopathological evaluation of the pancreas). The study results will form part of the documentation used in the certification process for the IVD (in vitro diagnostic) medical device developed by Urteste in Europe. Furthermore, they may potentially supplement the clinical data obtained in a planned study in the U.S. Development work on the Panuri test, completed in June 2025, provided preliminary data indicating the solution’s diagnostic potential, including a sensitivity of 89%, specificity of 75%, and diagnostic accuracy of 81% in the analyzed study population. The data obtained has attracted the interest of potential strategic partners. Urteste currently has 13 prototypes of diagnostic tests for cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas, and prostate, which together account for nearly 70% of all cancer-related deaths worldwide. The innovative technology developed by Urteste involves detecting cancers by measuring the activity of enzymes present in urine using specific tests that cause a change in urine color intensity, which may indicate the presence of cancer.
お知らせ • Jun 02Urteste S.A., Annual General Meeting, Jun 26, 2026Urteste S.A., Annual General Meeting, Jun 26, 2026.
New Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).
お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025
お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).
お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.
分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Dec 07Is Urteste (WSE:URT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jul 19Urteste (WSE:URT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • May 29Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain TumoursUrteste S.A. developed a prototype IVD test for detecting brain tumours. Urteste now has a pipeline of 12 prototype diagnostic tests for the following cancers: pancreatic, brain, breast, stomach, bile ducts, ovary, endometrial, kidney, colorectal, lung, liver and prostate accounting collectively for nearly 70% of all cancer deaths worldwide. In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its project PANURI, a test for pancreatic cancer. Urteste’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error. PANURI - the pancreatic cancer test is Urteste's most advanced project. Pancreatic cancer is one of the worst prognosis cancers. A proof-of-concept study of 322 participants confirmed the high sensitivity (95.6%) and specificity (95.5%) of the PANURI test. Urteste is currently undergoing an FDA Q-Submission programme. In the MULTI-CANCER project, Urteste is developing a diverse portfolio of tests. The company already has prototypes of 12 diagnostic tests for the most common cancers. In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests. The company will then focus on preparing for clinical trials. Urteste holds polish patents and international patent applications for its technology. Urteste's patent strategy is to seek patent protection in countries that collectively generate around 90% of global GDP.
お知らせ • May 21Urteste S.A., Annual General Meeting, Jun 14, 2024Urteste S.A., Annual General Meeting, Jun 14, 2024.
お知らせ • Jan 19+ 3 more updatesUrteste S.A. to Report Q3, 2024 Results on Nov 28, 2024Urteste S.A. announced that they will report Q3, 2024 results on Nov 28, 2024
New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (zł155.1m market cap, or US$38.0m).
お知らせ • May 31Urteste S.A., Annual General Meeting, Jun 22, 2023Urteste S.A., Annual General Meeting, Jun 22, 2023, at 14:00 Central European Standard Time.
お知らせ • May 28+ 1 more updateUrteste S.A. to Report First Half, 2023 Results on Sep 29, 2023Urteste S.A. announced that they will report first half, 2023 results on Sep 29, 2023
お知らせ • Jan 26+ 3 more updatesUrteste S.A. to Report Q3, 2023 Results on Nov 13, 2023Urteste S.A. announced that they will report Q3, 2023 results on Nov 13, 2023